Clinical Trial Update: A Study of Patients With Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma Treated With Lisocabtagene Maraleucel in the Post-Marketing Setting

View source ↗

Summary

This clinical trial update announces a study of lisocabtagene maraleucel for relapsed/refractory Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma in …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Chronic Lymphocytic Leukemia
• Small Lymphocytic Lymphoma

Drugs mentioned

• Breyanzi (lisocabtagene maraleucel)

Snippet

Sponsor: Juno Therapeutics, Inc., a Bristol-Myers Squibb Company | Conditions: Chronic Lymphocytic Leukemia (CLL), Small Lymphocytic Lymphoma (SLL) | Status: RECRUITING